INT182013

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2005
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 1.92
Pain Relevance 4.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Acr) protein complex (Acr)
Acr (Mus musculus)
Pain Link Frequency Relevance Heat
abatacept 120 99.68 Very High Very High Very High
Infliximab 359 98.72 Very High Very High Very High
rheumatoid arthritis 141 97.52 Very High Very High Very High
methotrexate 61 95.28 Very High Very High Very High
Pain 7 90.64 High High
Arthritis 57 85.36 High High
psoriasis 237 50.00 Quite Low
Inflammation 35 24.48 Low Low
cytokine 18 12.20 Low Low
Etanercept 24 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 141 97.52 Very High Very High Very High
Disease 164 94.28 High High
Pain 7 90.64 High High
Seronegative Spondarthritis 33 85.36 High High
Arthropathy 9 78.88 Quite High
Staphylococcus Infection 6 72.24 Quite High
Infection 42 71.52 Quite High
Opportunistic Infections 9 54.24 Quite High
Psoriasis 252 50.00 Quite Low
Cancer 22 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ACR response was recorded at 54 weeks [9].
Regulation (response) of ACR
1) Confidence 0.06 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1064892 Disease Relevance 0.60 Pain Relevance 0.41
ACR 20, ACR 50 and ACR 70 responses were maintained with continued infliximab treatment in the randomized infliximab group and were substantial following crossover to infliximab in the placebo/infliximab group.
Regulation (responses) of ACR associated with infliximab
2) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643098 Disease Relevance 0.21 Pain Relevance 0.76
ACR 20, ACR 50 and ACR 70 responses were maintained with continued infliximab treatment in the randomized infliximab group and were substantial following crossover to infliximab in the placebo/infliximab group.
Regulation (responses) of ACR 20 associated with infliximab
3) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643098 Disease Relevance 0.21 Pain Relevance 0.77
ACR 20, ACR 50 and ACR 70 responses were maintained with continued infliximab treatment in the randomized infliximab group and were substantial following crossover to infliximab in the placebo/infliximab group.
Regulation (responses) of ACR associated with infliximab
4) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643098 Disease Relevance 0.16 Pain Relevance 0.74
Data presented in abstract form only [21,22] demonstrate that response to therapy was maintained during the second 6 months of blinded therapy, as measured by both ACR response and improvement in 36-item Short Form parameters.
Regulation (response) of ACR
5) Confidence 0.03 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.31 Pain Relevance 0.65
ACR 50 response was achieved by 56% of those patients who remained on therapy at 1 year and by 54.7% of those who remained on therapy at 2 years [23]; 48% of patients who remained on therapy achieved remission by Disease Activity Score criteria at 1 year that was sustained through 2 years [24].
Regulation (response) of ACR associated with disease
6) Confidence 0.03 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.34 Pain Relevance 0.63
Again, ACR 20 responses in the abatacept 2 mg/kg and placebo groups were not statistically different.
Regulation (responses) of ACR associated with abatacept
7) Confidence 0.03 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.08 Pain Relevance 0.62

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox